Company / R&D Expense
Vanda Pharmaceuticals Inc. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$76.8M
FY2025
5-year range
$48.6M / $85.8M
FY2021-FY2025
Trend
-10.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
$77M in FY2025 with a 5-year CAGR of +12.0%.
Remained stable around $77M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +11.4%
- 5-Year CAGR
- +12.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +12.0%, indicating consistent growth.
- In FY2025, r&d expense decreased 10.4% year-over-year.
- Peak r&d expense was recorded in FY2024.
- Lowest r&d expense in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -3.96 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $76.8M | -10.4% |
| FY2024 | $85.8M | +13.8% |
| FY2023 | $75.4M | +35.6% |
| FY2022 | $55.6M | +14.2% |
| FY2021 | $48.6M | +11.6% |
| FY2020 | $43.6M | +13.1% |
| FY2019 | $38.5M | +32.2% |
| FY2018 | $29.2M | +0.0% |
| FY2017 | $29.1M | +51.6% |
| FY2016 | $19.2M | -32.5% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026